Back

Variability in lipoprotein(a) measurements in ODYSSEY OUTCOMES: is one-and-done testing sufficient?

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Implementing novel lipid‑lowering therapies Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

4 More presentations in this session

Presentation thumbnail
The nocebo effect in statin therapy: clinical implications for adherence and cardiovascular outcomes
Doctor M. Sargsyan (Yerevan, AM)
Abstract Slides Video
Presentation thumbnail
Comparative effectiveness of lipid-lowering regimens for achieving ESC LDL-cholesterol targets in acute coronary syndrome: a real-world cohort analysis
Doctor A. Romiou (Marousi, GR)
Abstract Slides Video
Presentation thumbnail
Nationwide implementation of PCSK9--targeted therapies after myocardial infarction and ischemic stroke: structural barriers and disparities in a universal healthcare system
Assistant Professor P. Sedova (Brno, CZ)
Abstract Slides Video
Presentation thumbnail
Atorvastatin for prevention of chemotherapy-induced cardiotoxicity: a 5-year propensity-matched cohort study of 800 patients
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides Video

Access the full session

Session thumbnail
Implementing novel lipid‑lowering therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Intra-individual lipoprotein(a) variability and risk reclassification in patients with cardiovascular disease
30 August 2026
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
31 August 2025
thumbnail
Congress Presentation
Raised lipoprotein(a) associates with rapidly progressive coronary atherosclerosis after acute coronary syndrome
30 August 2026
thumbnail
Congress Presentation
Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources